Experience in prevention of neutropenia in patients with disseminated soft tissue sarcomas receiving polychemotherapy


Cite item

Full Text

Abstract

The main treatment for metastatic soft tissue sarcomas is chemotherapy (CT); neutropenia is its frequent complication that is treated with various colony stimulating factors (CSFs). The purpose of the study was to assess the treatment effectiveness and frequency of adverse events in administration of various CSFs (filgrastim, pegfilgrastim and lipegfilgrastim) in patients with disseminated soft tissue sarcomas receiving myelosuppressive CT. Data on 34 patients firstly diagnosed with disseminated soft tissue sarcomas were studied; the patients received 4 cycles of CT: doxorubicin plus ifosfamide, combined with CSFs: filgrastim daily or a single injection of long-acting CSFs. Following results were received: both duration and severity of neutropenia were highest in the filgrastim group. Frequency of febrile neutropenia requiring antibacterial treatment and the number of cases of discontinuation of cytostatics or dose reduction associated with hematological complications during the cycles 1-4 were significantly lower in patients receiving pegfilgrastim and lipegfilgrastim. Musculoskeletal pain was the most frequent adverse event during cytokine administration. Thus, a single injection of pegfilgrastim and lipegfilgrastim contributed to a significant reduction of neutropenia duration and severity, compared with daily filgrastim, with similar safety profiles of the drugs.

About the authors

L Yu Vladimirova

Rostov Research Institute of Oncology

д-р мед. наук, проф., зав. отд-нием противоопухолевой лекарственной терапии №1 ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

I S Mitashok

Rostov Research Institute of Oncology

зав. отд-нием противоопухолевой лекарственной терапии №2 ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

T A Snezhko

Rostov Research Institute of Oncology

Email: tatyana_snezhko@mail.ru
канд. мед. наук, врач-онколог отд-ния противоопухолевой лекарственной терапии №2 ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

N Yu Samaneva

Rostov Research Institute of Oncology

врач-онколог отд-ния противоопухолевой лекарственной терапии №2 ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

A E Storozhakova

Rostov Research Institute of Oncology

канд. мед. наук, врач-онколог отд-ния противоопухолевой лекарственной терапии №1 ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

I S Kornilova

Rostov Research Institute of Oncology

врач-онколог отд-ния противоопухолевой лекарственной терапии №2 ФГБУ РНИОИ 344037, Russian Federation, Rostov-on-Don, ul. 14-ia Liniia, d. 63

References

  1. Горбунова В.А. Новые подходы в лекарственном лечении сарком мягких тканей. Поволжский онкологический вестник. 2012; 2: 25-34.
  2. Кит О.И., Касаткин В.Ф., Максимов А.Ю. и др. Факторы, влияющие на выживаемость больных с неорганными забрюшинными опухолями. Паллиативная медицина и реабилитация. 2012; 2: 16-9.
  3. Kuderer N.M, Dale D.C, Crawford J et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106 (10): 2258-66.
  4. Fortner B.V, Houts A.C, Shwartzberg L.S. A prospective investigator of chemotherapy - induced neutropenia and quality of life. J Support Oncol 2006; 4 (9): 472-78.
  5. Феденко А.А., Строяковский Д.Л. Пэгфилграстим в профилактике и лечении постцитостатической болезни. Саркомы костей, мягких тканей и опухоли кожи. 2010; 3: 54-62.
  6. Птушкин В.В., Жуков Н.В., Борисов В.И. и др. Профилактика нейтропении при химиотерапии миелостимуляторами пролонгированного действия. Онкогематология. 2015; 2 (10): 37-45.
  7. Adjuvant therapy for breast cancer. NIH Consens Statement 2000; 17 (4): 1-35.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies